Editorial commentary: MicroRNAs as effectors and indicators of aspirin therapeutic potential

Trends Cardiovasc Med. 2020 Jul;30(5):255-256. doi: 10.1016/j.tcm.2019.09.002. Epub 2019 Sep 14.

Authors

Jacob B Pierce¹, Mark W Feinberg²

Affiliations

¹ Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.
² Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA, 02115, United States. Electronic address: mfeinberg@bwh.harvard.edu.

PMID: 31547951
DOI: 10.1016/j.tcm.2019.09.002

No abstract available

Keywords: Aspirin; Cardiovascular disease; microRNAs.

Publication types

Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Aspirin
Cardiovascular Diseases*
Humans
MicroRNAs*
Platelet Aggregation Inhibitors

Substances

MicroRNAs
Platelet Aggregation Inhibitors
Aspirin